Faculty Profile

Dr. Murali Janakiram, M.B.B.S.

Murali Janakiram, M.B.B.S.

Assistant Professor, Department of Medicine (Oncology)

Areas of Research: Adult T cell leukemia lymphoma, HIV related lymphoma, Immune checkpoints PDL1, B7H3, B7x and HHLA2 expression in cancers

Professional Interests

Adult T cell leukemia lymphoma, HIV related lymphoma, T and B cell Lymphomas, Immune checkpoints PDL1, B7H3, B7x and HHLA2 expression in cancers

Selected Publications

Research Articles:

1.Adult T-Cell Leukemia/Lymphoma in the Caribbean cohort – pathological features, cytogenetics, and response to standard therapy and transplantation.

Zell M, Assal A, Derman O, Kornblum N, Battini R, Wang Y, Mantzaris I, Shastri A, Verma A, Ye H, Braunschweig I, Janakiram M Oncotarget. 2016 Jun 22. 

2. HHLA2, a new immune checkpoint member of the B7 family, is widely expressed in human lung cancer and associated with EGFR mutational status.

Cheng H, Janakiram M (co first author), Borczuk A, Lin J, Qiu W, Liu H, Chinai J, Halmos B, Perez-Soler R, Zang X. Clin Cancer Res. 2016 Aug 23

3. Expression, clinical significance, and receptor identification of the newest B7 family member HHLA2 protein.

Janakiram M, Chinai J, Fineberg S, Fiser A, Montagna C, Medaverepu R, Castano E6, Jeon H1, Ohaegbulam KC, Zhao R, Zhao A, Almo S, Sparano JA, Zang X. Clin Cancer Res. 2014 Dec 30.1495.2014. PMID: 25549724

4. Structure and cancer immunotherapy of the B7 family member B7x (B7-H4/B7S1).

Jeon H, Vigdorovich V, Garrett-Thomson SC, Janakiram M, Ramagopal UA, Abadi YM, Lee JS, Scandiuzzi L, Ohaegbulam KC, Chinai JM, Zhao R, Yao Y, Mao Y, Sparano JA, Almo SC, Zang X. Cell Reports, 9:1089-1098, 2014, PMID: 25437562

5. Analysis of chronic myelogenous leukemia in an underserved, inner-city cohort shows a significant five year overall survival that is not affected by choice of tyrosine kinase inhibitor.

Assal A, Dong B, Khan H, Medavarapu R, Shastri A, Pradhan K, Friedman E, Mantzaris I, Janakiram M, Battini R, Kornblum N, Yu Y, Verma A, Braunschweig I, Derman O. Leuk Lymphoma. 2016 Feb 17:1-4. [Epub ahead of print] PMID: 26886689

6. A Systematic Review of the Utility of Residual Vein Obstruction Studies in Primary and Secondary Venous Thrombosis

Janakiram M, Sullivan M, Shcherba M, Guo S, Billett HH Thrombosis. 2013; 2013:247913, PMID: 24349773

Review articles and Case Reports:

1. HHLA2 and TMIGD2: New immunotherapeutic targets of the B7 and CD28 families.

Janakiram M, Chinai J, Zhao A, Sparano JA, Zang X Oncoimmunology. 2015 Apr 14;4(8): eCollection 2015 Aug. PMID: 26405587

2. Immunotherapies targeting the PD-1 pathway.

Chinai J, Janakiram M, Zang X Trends Pharmacol Sci (Cell Press). 2015 Sep;36(9):587-95. Epub 2015 Jul 7. Review. PMID: 26162965

3.Immune checkpoint blockade in human cancer therapy: lung cancer and hematologic malignancies. 

Janakiram M, Pareek V, Cheng H, Narasimhulu DM, Zang X. Immunotherapy 8 (7), 809-819

4. Lenalidomide in the treatment of Rosai Dorfman disease-a first in use report.

Rubinstein M, Assal A, Scherba M, Elman J, White R, Verma A, Strakhan M, Mohammadi F, Janakiram M. Am J Hematol. 2016 Feb;91(2) PMID: 26502013

5. T cell Coinhibition and Immunotherapy in Human Breast Cancer.

Janakiram M, Abadi YM, Sparano JA, Zang X Discov Med. 2012 Oct; 14(77):229-36 PMID: 23114578

6. Current and Emerging Therapies in primary myelofibrosis.

Ayyappan S, Janakiram M, Ragupathy R Cardiovasc Hematol Drug Targets. 2012 Sep; 12(1):6-20 PMID: 22746348

7. Emerging Therapeutic Targets in Diffuse Large B-Cell Lymphoma.

Janakiram M, Thirukonda VK, Sullivan M, Petrich AM. Curr Treat Options Oncol. 2012 Feb 2. PMID: 22297843

Posters /Abstracts:

1. Cell of Origin By Immunohistochemistry Is Not Prognostic of Overall Survival in HIV Associated DLBCL-Analysis of Clinical Pathological Markers in HIV DLBCL. Nandikolla AG, Wang Y, Shah UA, Derman O, Kornblum N, Mantzaris I, Shastri A, Khan H, Kim N, Grant M, Brausnchweig I, Ye BH, Verma A, Janakiram M

2.Progressive Multifocal Leukoencephalopathy Associated with Hematopoietic Stem Cell Transplant (HSCT) Has Better Prognosis Than PML Associated with Monoclonal Antibodies or Chemotherapy in Hematological Malignancies: Analysis of a Case Series Raajasekar AKA, Ayyapan S, Khan H, Mantzaris I, Janakiram M Biology of Blood and Marrow Transplant 22 (3), S153-S154

3. Plasmablastic Lymphoma: A Case Series of the Changing Epidemiology of a Rare Extramedullary Plasmacytoid Neoplasm, Diagnostic Challenges, and Therapeutic Implications. Lee XL, Konda B, Assal A, Zell MI, Braunschweig I, Derman O, Kornblum N, Verma A, Battini R, Janakiram M Blood: 124 (21), December 2014

4. Tumor infiltrating lymphocytes (TILs) in breast cancer: A meta-analysis of response to neoadjuvant chemotherapy based on TIL status Janakiram M, Zhang L, White R, Ayyappan S, Sparano J, San Antonio Breast Cancer Symposium 2013

5. The prognostic significance of B7 ligands (HHLA2) in breast cancer. Janakiram M, Fineberg S, Sparano J, Zang X ECOG-ACRIN conference - November 2013

6. Pegfilgrastim Use and Risk of Bleomycin Induced Pulmonary Toxicity in Hodgkin Lymphoma Janakiram M, O’Brien T .Blood (ASH Annual Meeting Abstracts), Nov 2008; 112: 4950


Material in this section is provided by individual faculty members who are solely responsible for its accuracy and content.

Montefiore Medical Center
111 East 210th Street
Hofheimer Main, Room 100
Bronx, NY 10467

Tel: 718.920.4826
Fax: 718.798.7474

Research Information